ADTX · Aditxt, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12.2K | - | $748 | $1.0K | $1.0K | - | $6.9K | $44.3K | $79.7K | - |
| Cost of Revenue | $9.3K | - | $732 | $1.0K | $734 | - | $106.9K | $23.1K | $65.8K | - |
| Gross Profit | $2.9K | - | $16 | ($1) | $284 | - | ($460.7K) | $21.1K | $13.9K | - |
| R&D | $1.05M | - | $672.0K | $764.3K | $1.21M | - | $491.6K | $1.55M | $8.15M | - |
| SG&A | $3.32M | - | $2.46M | $5.04M | $4.35M | - | $3.72M | $4.42M | $3.36M | - |
| Total Operating Expenses | $4.36M | - | $3.14M | $6.15M | $5.61M | - | $4.24M | $6.00M | $11.55M | - |
| D&A | $47.9K | - | $66.7K | $67.0K | $68.5K | - | $148.3K | $157.2K | $142.9K | - |
| Operating Income | ($4.36M) | - | ($3.14M) | ($6.15M) | ($5.61M) | - | ($4.70M) | ($5.98M) | ($11.54M) | - |
| Interest Expense | $27.1K | - | $176.5K | $1.09M | $2.49M | - | $906.1K | - | - | - |
| Income Tax | - | - | - | - | - | - | - | - | - | - |
| Net Income | ($15.95M) | - | ($24.05M) | ($7.26M) | ($5.71M) | - | ($12.85M) | ($7.55M) | ($14.73M) | - |
| EPS - Basic | ($790.49) | - | ($118536.48) | ($84207.60) | ($198192.96) | - | ($677749140.00) | ($1022695200.00) | ($2230891200.00) | - |
| EPS - Diluted | ($790.49) | - | ($118536.48) | ($84207.60) | ($198192.96) | - | ($677749140.00) | ($1022695200.00) | ($2247976800.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $268.9K | $3.20M | $163.0K | $323.7K | $476.4K | $833.0K | $328.6K | $91.2K | $88.7K | $97.1K |
| Accounts Receivable | $12.0K | - | $39.2K | $39.7K | $42.1K | $43.4K | $351.7K | $406.6K | $427.0K | - |
| Inventory | $128.4K | $5.8K | $6.6K | $7.6K | $9.1K | $11.2K | $89.0K | $565.5K | $622.8K | $745.5K |
| Accounts Payable | $7.73M | $7.34M | $10.36M | $9.68M | $6.65M | $10.19M | - | - | - | $7.52M |
| Current Assets | $850.0K | $3.82M | $420.4K | $433.7K | $1.22M | $2.00M | $2.09M | $1.51M | $1.60M | $6.91M |
| Total Assets | $13.91M | $16.52M | $11.80M | $32.69M | $31.22M | $32.14M | $29.84M | $28.37M | $27.98M | $44.58M |
| Current Liabilities | $13.34M | $12.22M | $20.66M | $20.58M | $15.18M | $23.41M | $24.37M | $20.57M | $17.30M | $25.89M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $49.08M | $12.56M | $20.66M | $20.70M | $15.46M | $23.86M | $25.39M | $22.03M | $18.19M | $28.53M |
| Stockholders' Equity | ($33.28M) | $5.61M | ($7.73M) | $12.96M | $16.59M | $496.6K | $4.71M | $6.57M | $9.93M | $16.06M |
| Retained Earnings | ($225.76M) | ($209.81M) | ($205.11M) | ($181.06M) | ($173.80M) | ($168.09M) | ($162.87M) | ($150.02M) | ($142.47M) | ($127.74M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($4.58M) | - | - | - | ($11.71M) | - | - | - | ($5.96M) | - |
| Investing Cash Flow | ($10.4K) | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | $1.66M | - | - | - | $11.36M | - | - | - | $5.95M | - |
| CapEx | $10.4K | - | - | - | - | - | - | - | $5.0K | - |
| Free Cash Flow | ($4.59M) | - | - | - | - | - | - | - | ($5.97M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 23.6% | - | 2.1% | -0.1% | 27.9% | - | -6721.4% | 47.8% | 17.4% | - |
| Operating margin | -35873.5% | - | -419870.3% | -612788.3% | -550895.4% | - | -68588.2% | -13497.1% | -14477.5% | - |
| EBITDA margin | -35479.7% | - | -410953.5% | -606110.4% | -544171.4% | - | -66425.2% | -13142.1% | -14298.1% | - |
| Net margin | -131159.8% | - | -3214626.3% | -722789.6% | -560934.1% | - | -187445.6% | -17051.3% | -18486.1% | - |
| Free cash flow margin | -37742.3% | - | - | - | - | - | - | - | -7487.4% | - |
| FCF / Net income | 0.29 | - | - | - | - | - | - | - | 0.41 | - |
| R&D / Revenue | 8611.6% | - | 89845.6% | 76128.2% | 118782.4% | - | 7171.8% | 3508.4% | 10222.5% | - |
| SG&A / Revenue | 27285.5% | - | 329219.4% | 501896.0% | 427138.9% | - | 54257.4% | 9981.8% | 4221.6% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -114.7% | - | -203.8% | -22.2% | -18.3% | - | -43.1% | -26.6% | -52.7% | - |
| Return on equity | 47.9% | - | 311.0% | -56.0% | -34.4% | - | -272.7% | -115.0% | -148.3% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 0.06 | 0.31 | 0.02 | 0.02 | 0.08 | 0.09 | 0.09 | 0.07 | 0.09 | 0.27 |
| Quick ratio | 0.05 | 0.31 | 0.02 | 0.02 | 0.08 | 0.08 | 0.08 | 0.05 | 0.06 | 0.24 |
| Cash ratio | 0.02 | 0.26 | 0.01 | 0.02 | 0.03 | 0.04 | 0.01 | 0.00 | 0.01 | 0.00 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | -160.7x | - | -17.8x | -5.6x | -2.3x | - | -5.2x | - | - | - |
| Equity multiplier | -0.42 | 2.94 | -1.53 | 2.52 | 1.88 | 64.73 | 6.33 | 4.32 | 2.82 | 2.78 |
| Liabilities / Assets | 3.53 | 0.76 | 1.75 | 0.63 | 0.50 | 0.74 | 0.85 | 0.78 | 0.65 | 0.64 |
| Efficiency | ||||||||||
| Asset turnover | 0.00 | - | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 | - |
| Inventory turnover | 0.07 | - | 0.11 | 0.13 | 0.08 | - | 1.20 | 0.04 | 0.11 | - |
| Days sales outstanding | 359d | - | 19120d | 14448d | 15101d | - | 18730d | 3352d | 1956d | - |
| Days inventory outstanding | 5043d | - | 3277d | 2766d | 4504d | - | 304d | 8922d | 3455d | - |
| Days payable outstanding | 303626d | - | 5167218d | 3515840d | 3308935d | - | - | - | - | - |
| Cash conversion cycle | -298224d | - | -5144821d | -3498625d | -3289330d | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | - | 5066.9x | 4643.4x | - | 641157.7x | 91789186.3x | 134619584.2x | - |
| P / S | 43.9x | - | 1075180.0x | 65400246.6x | 75668206.8x | - | 440757911.9x | 13612268336.3x | 16777328920.5x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | 1094.4% | - | -89.1% | -97.7% | -98.7% | - | -94.5% | -80.0% | -63.5% | - |
| Revenue CAGR (3y) | -61.8% | - | -86.8% | -83.3% | -83.1% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | 909.9% | - | - | - | -98.0% | - | - | -40.0% | -65.4% | - |
| Operating income growth (YoY) | 22.2% | - | 33.2% | -3.0% | 51.4% | - | 41.9% | -41.1% | -99.5% | - |
| Net income growth (YoY) | -179.3% | - | -87.2% | 3.9% | 61.2% | - | -31.8% | -32.9% | -146.1% | - |
| EPS growth (YoY) | 99.6% | - | 100.0% | 100.0% | 100.0% | - | -1413449618.5% | -109967225706.5% | -171601282342.7% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | - | 1029.7% | - | 97.4% | 67.1% | -96.9% | - | - | 14488.8% | 208.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Aditxt against the 5 most active filers in the same SIC group.